|
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
|
|
|
|
rs121909219
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs751409106
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
|
rs80358683
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs619586
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Conclusions:</b> Our findings su</span>ggested that MALAT1 SNP rs619586 could serve as a potential indicator for PTC susceptibility and pathogenesis.
|
31788131 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>Purpose:</b> Sixty percent of papillary thyroid cancers (PTC) have an oncogenic (V600E) BRAF mutation.
|
30065097 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<b>Purpose:</b> Sixty percent of papillary thyroid cancers (PTC) have an oncogenic (V600E) BRAF mutation.
|
30065097 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<i>BRAF</i>V600E (c.1799T>A) somatic mutation evaluation in fine needle aspiration biopsies (FNAB) is a powerful diagnostic tool in the settings of papillary thyroid cancer (PTC).
|
30374428 |
2018 |
|
rs360717
|
|
|
0.010 |
GeneticVariation |
BEFREE |
3 SNPs of IL-18 (rs549908, rs360717, and rs187238) and one of IL-18R (rs1420106) examined in this study were significantly associated with the development of PTC.
|
26600055 |
2015 |
|
rs187238
|
|
|
0.010 |
GeneticVariation |
BEFREE |
3 SNPs of IL-18 (rs549908, rs360717, and rs187238) and one of IL-18R (rs1420106) examined in this study were significantly associated with the development of PTC.
|
26600055 |
2015 |
|
rs1420106
|
|
|
0.010 |
GeneticVariation |
BEFREE |
3 SNPs of IL-18 (rs549908, rs360717, and rs187238) and one of IL-18R (rs1420106) examined in this study were significantly associated with the development of PTC.
|
26600055 |
2015 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
38.2% of human PTCs displayed high expression of AXL that positively correlated with RAI-refractoriness and disease persistence or recurrence, especially when combined with v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation.
|
31181609 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
38.2% of human PTCs displayed high expression of AXL that positively correlated with RAI-refractoriness and disease persistence or recurrence, especially when combined with v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation.
|
31181609 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
42 (37 PTC; 5 benign) surgical tissue samples were analysed for the BRAF V600E activating point mutation.
|
17298986 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
42 (37 PTC; 5 benign) surgical tissue samples were analysed for the BRAF V600E activating point mutation.
|
17298986 |
2007 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
58% PTCs presented a genetic alteration either RET/PTC rearrangement, BRAF V599E mutation or both: three cases of PTCs (25%) presented a RET/PTC rearrangement; three cases of PTCs (25%) presented a BRAF V599E mutation and in one case (8%) both alterations were identified.
|
15859312 |
2005 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
58% PTCs presented a genetic alteration either RET/PTC rearrangement, BRAF V599E mutation or both: three cases of PTCs (25%) presented a RET/PTC rearrangement; three cases of PTCs (25%) presented a BRAF V599E mutation and in one case (8%) both alterations were identified.
|
15859312 |
2005 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
80 (60.61%) of papillary thyroid carcinomas exhibited BRAF(V600E) mutation in a range of 7.7% to 46.3% of the total BRAF alleles.
|
25400776 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
80 (60.61%) of papillary thyroid carcinomas exhibited BRAF(V600E) mutation in a range of 7.7% to 46.3% of the total BRAF alleles.
|
25400776 |
2014 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
99 PTC and 11 nodular hyperplasia FFPE thyroid tissues are evaluated for the BRAF V600E mutation by the Idylla tests and compared with peptide nucleic acid-clamping PCR, real-time PCR and pyrosequencing.
|
27543599 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
99 PTC and 11 nodular hyperplasia FFPE thyroid tissues are evaluated for the BRAF V600E mutation by the Idylla tests and compared with peptide nucleic acid-clamping PCR, real-time PCR and pyrosequencing.
|
27543599 |
2017 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Papillary thyroid cancer subjects harboring RET/PTC rearrangements developed this cancer earlier than did cases with BRAF(V600E) mutation (P = 0.03).
|
18757433 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Papillary thyroid cancer subjects harboring RET/PTC rearrangements developed this cancer earlier than did cases with BRAF(V600E) mutation (P = 0.03).
|
18757433 |
2008 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors the oncogenic T1799A BRAF mutation.
|
19883729 |
2010 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
PTC cases were also examined for their BRAF(V600E) mutational status.
|
21730105 |
2011 |